Establishing a precise system of damage early-warning and surgical intervention for obstructive sleep apnea hypopnea syndrome

Establishing a precise system of damage early-warning and sugical intervention for obstructive sleep apnea hypopnea syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037152

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive sleep apnea hypopnea syndrome

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Volunteering to participate in this clinical study and sign an informed consent form; 2. Gender is not limited, and the baseline age is >= 18 years old; 3. Keeping complete baseline demographic information, medical history information, anthropometric data, questionnaire information, PSG data, biochemical indicator information and biological samples; 4. The total sleep duration of baseline PSG examination is >= 4 hours, and the sleep duration of rapid eye movement and NREM periods are both >= 0.5 hours; 5. Willing to cooperate in completing the follow-up; 6. Did not participate in other clinical research projects in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Previously diagnosed as other sleep-disordered breathing diseases other than OSAHS, such as central sleep apnea syndrome, sleep-related alveolar hypopnea, sleep-related hypoxemia, etc.; 2. Severe psychiatric diseases such as mania and schizophrenia; 3. Suffering from infectious diseases such as tuberculosis, AIDS, and syphilis; 4. Pregnant women; 5. Those who have used steroid hormones or hormone replacement therapy for a long time; 6. Acute inflammatory reaction period; 7. Unable to cooperate in completing various inspections and inspections, or unable to provide biological samples.

Design outcomes

Primary

Measure	Time frame
blood glucose;Blood pressure;	—

Secondary

Measure	Time frame
Blood lipids;glycosylated hemoglobin;Fasting plasma insulin;Fasting blood glucose;Ventricular wall thickness;Left ventricular mass;Carotid inner diameter;Carotid intima thickness;Carotid plaque;Quebec Sleep Questionnaire Score;Montreal Cognitive Assessment Test Form Score;Mini-Mental State Examination Score;Hospital Anxiety and Depression Scale Score;Functional sleep outcome questionnaire Score;Trail Making Test A Score;Electrocardiogram;Height;Weight;liver function;Kidney function;	—

Measure

Time frame

Blood lipids;glycosylated hemoglobin;Fasting plasma insulin;Fasting blood glucose;Ventricular wall thickness;Left ventricular mass;Carotid inner diameter;Carotid intima thickness;Carotid plaque;Quebec Sleep Questionnaire Score;Montreal Cognitive Assessment Test Form Score;Mini-Mental State Examination Score;Hospital Anxiety and Depression Scale Score;Functional sleep outcome questionnaire Score;Trail Making Test A Score;Electrocardiogram;Height;Weight;liver function;Kidney function;

—

Countries

China

Contacts

Public ContactShankai Yin

Shanghai Sixth People's Hospital

skyin@sjtu.edu.cn+86 18930177096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026